These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 23354523)
1. Assessing patterns of use of cardio-protective polypill component medicines in Australian women. Stewart Williams JA; Wallick CJ; Byles JE; Doran CM Drugs Aging; 2013 Mar; 30(3):193-203. PubMed ID: 23354523 [TBL] [Abstract][Full Text] [Related]
2. The Effect of a Cardiovascular Polypill Strategy on Pill Burden. Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R; Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247 [TBL] [Abstract][Full Text] [Related]
3. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A; Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715 [TBL] [Abstract][Full Text] [Related]
4. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A; Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727 [TBL] [Abstract][Full Text] [Related]
5. Combined use of polypill components in patients with type 2 diabetes mellitus. Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M; Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753 [TBL] [Abstract][Full Text] [Related]
6. Associations Between Statin Use and Physical Function in Older Adults from The Netherlands and Australia: Longitudinal Aging Study Amsterdam and Australian Longitudinal Study on Women's Health. van Boheemen L; Tett SE; Sohl E; Hugtenburg JG; van Schoor NM; Peeters GM Drugs Aging; 2016 Jun; 33(6):437-45. PubMed ID: 27138957 [TBL] [Abstract][Full Text] [Related]
7. The concept of the polypill in the prevention of cardiovascular disease. Wiley B; Fuster V Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562 [TBL] [Abstract][Full Text] [Related]
8. The evening versus morning polypill utilization study: the TEMPUS rationale and design. Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539 [TBL] [Abstract][Full Text] [Related]
9. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis. Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687 [TBL] [Abstract][Full Text] [Related]
10. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Bautista LE; Vera-Cala LM; Ferrante D; Herrera VM; Miranda JJ; Pichardo R; Sánchez Abanto JR; Ferreccio C; Silva E; Oróstegui Arenas M; Chirinos JA; Medina-Lezama J; Pérez CM; Schapochnik N; Casas JP Health Aff (Millwood); 2013 Jan; 32(1):155-64. PubMed ID: 23297283 [TBL] [Abstract][Full Text] [Related]
11. Improving cardiovascular protection: focus on a cardiovascular polypill. Barrios V; Escobar C Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213 [TBL] [Abstract][Full Text] [Related]
12. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy? Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098 [TBL] [Abstract][Full Text] [Related]
13. Polypill Strategy in Secondary Cardiovascular Prevention. De la Rosa A; Arrington K; Desai R; Acharya PC Curr Cardiol Rep; 2024 May; 26(5):443-450. PubMed ID: 38557814 [TBL] [Abstract][Full Text] [Related]
14. [The polypill: optimal strategy for reduction of cardiovascular disease]. Nathoe HM; Doevendans PA Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290 [TBL] [Abstract][Full Text] [Related]
15. The polypill to prevent cardiovascular disease: physicians' perspectives. Viera AJ Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826 [TBL] [Abstract][Full Text] [Related]
16. Could the polypill improve adherence? The patient perspective. Bryant L; Martini N; Chan J; Chang L; Marmoush A; Robinson B; Yu K; Wong M J Prim Health Care; 2013 Mar; 5(1):28-35. PubMed ID: 23457692 [TBL] [Abstract][Full Text] [Related]
17. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk. Bramlage P; Sims H; Minguet J; Ferrero C Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363 [TBL] [Abstract][Full Text] [Related]
18. An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Laba TL; Hayes A; Lo S; Peiris DP; Usherwood T; Hillis GS; Rafter N; Reid CM; Tonkin AM; Webster R; Neal BC; Cass A; Patel A; Rodgers A; Jan S Med J Aust; 2014 Dec; 201(11):671-3. PubMed ID: 25495315 [TBL] [Abstract][Full Text] [Related]
19. Is a statin as part of a polypill the answer? Robinson JG Curr Atheroscler Rep; 2009 Jan; 11(1):15-22. PubMed ID: 19080723 [TBL] [Abstract][Full Text] [Related]
20. Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Viera AJ; Sheridan SL; Edwards T; Soliman EZ; Harris R; Furberg CD Prev Med; 2011 Jan; 52(1):10-5. PubMed ID: 20933538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]